Key Points
- Director Coelho Rogerio Vivaldi sold 5,000 Crinetics shares on March 12 at an average price of $36.15 for a total of $180,750, reducing his position by 23.47% to 16,300 shares valued at about $589,245.
- Crinetics (NASDAQ:CRNX) opened at $37.49 with a 1‑year range of $24.10–$57.99, 50/200‑day moving averages of $46.96/$43.71, a market cap of roughly $3.93 billion, and a negative P/E of -7.59.
- Analyst sentiment is mixed-to-positive, with an average rating of “Moderate Buy” and a consensus price target of $74.78 (breakdown: 1 Strong Buy, 9 Buy, 1 Sell), while some firms have raised price targets and ratings recently.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) Director Coelho Rogerio Vivaldi sold 5,000 shares of the business's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $36.15, for a total transaction of $180,750.00. Following the sale, the director directly owned 16,300 shares in the company, valued at $589,245. The trade was a 23.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Crinetics Pharmaceuticals Price Performance
NASDAQ:CRNX opened at $37.49 on Friday. Crinetics Pharmaceuticals, Inc. has a 1 year low of $24.10 and a 1 year high of $57.99. The stock's fifty day moving average price is $46.96 and its two-hundred day moving average price is $43.71. The company has a market cap of $3.93 billion, a P/E ratio of -7.59 and a beta of 0.23.
Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($1.29) EPS for the quarter, topping analysts' consensus estimates of ($1.37) by $0.08. Crinetics Pharmaceuticals had a negative return on equity of 41.46% and a negative net margin of 6,046.22%.The firm's quarterly revenue was up NaN% compared to the same quarter last year. During the same period last year, the company earned ($0.88) earnings per share. On average, analysts expect that Crinetics Pharmaceuticals, Inc. will post -3.73 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on the company. Wall Street Zen upgraded Crinetics Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th. Morgan Stanley upped their target price on shares of Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the stock an "overweight" rating in a report on Tuesday, January 6th. Lifesci Capital raised shares of Crinetics Pharmaceuticals to a "strong-buy" rating in a report on Friday, February 13th. Citizens Jmp reduced their price target on shares of Crinetics Pharmaceuticals from $105.00 to $96.00 and set a "market outperform" rating for the company in a research report on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Crinetics Pharmaceuticals in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Crinetics Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $74.78.
View Our Latest Analysis on Crinetics Pharmaceuticals
Institutional Investors Weigh In On Crinetics Pharmaceuticals
Hedge funds have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its position in Crinetics Pharmaceuticals by 107.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 639 shares of the company's stock worth $30,000 after buying an additional 331 shares during the last quarter. Farther Finance Advisors LLC raised its stake in shares of Crinetics Pharmaceuticals by 523.7% during the third quarter. Farther Finance Advisors LLC now owns 842 shares of the company's stock worth $35,000 after acquiring an additional 707 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Crinetics Pharmaceuticals in the 2nd quarter worth approximately $30,000. Parallel Advisors LLC boosted its stake in shares of Crinetics Pharmaceuticals by 34.6% in the 4th quarter. Parallel Advisors LLC now owns 1,225 shares of the company's stock valued at $57,000 after purchasing an additional 315 shares in the last quarter. Finally, Covestor Ltd grew its holdings in shares of Crinetics Pharmaceuticals by 23,983.3% during the 3rd quarter. Covestor Ltd now owns 1,445 shares of the company's stock valued at $60,000 after purchasing an additional 1,439 shares during the last quarter. Institutional investors own 98.51% of the company's stock.
About Crinetics Pharmaceuticals
(
Get Free Report)
Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.
The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
